
Gene knockout cell lines are generated using CRISPR-Cas9 based technology to precisely disrupt target genes, enabling functional genomics research, disease modeling, and target validation.
ATG5 (autophagy related 5) encodes an essential component of the autophagy machinery that forms an E1-like activating complex with ATG12. ATG5 is required for autophagic vesicle formation and contributes to mitochondrial quality control, innate immune regulation, lymphocyte development, antigen presentation, adipocyte differentiation, and apoptosis. It therefore plays a central role in cellular degradation and homeostasis.
143B is a human osteosarcoma cell line derived indirectly from the HOS osteosarcoma cell line. The cells are deficient in thymidine kinase (TK−) and resistant to bromodeoxyuridine (BUdR). 143B is used as a model for studying osteosarcoma biology, tumor metabolism, and genetic selection systems involving thymidine kinase deficiency.
Comprehensive quality control includes STR authentication, sterility testing (bacteria and fungi), and mycoplasma screening to ensure purity and performance. Genotype is confirmed by two rounds of PCR and Sanger sequencing, and complete validation reports are provided for make-to-order products.

Cas9 cell lines in our cell bank can stably express Cas9 protein. Each Cas9 Stable Cell Line is easy to use and enables gene knockout simply by transfecting gRNA, while transfection of gRNA and donor DNA results in gene knock-in or point mutations
These Cas9 stable cell lines have been used to construct the KO cell lines for various genes, gene KO efficiency 5-10 times improved.
Selected cells, low passages, good cell condition, high activity, applicable for all kinds of gene-editing experiments.

Targeted knockout region: EExon 4
Reference Transcript: NM_004849
Frameshift Mutation Strategy
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use






Simply fill out the form below to leave your inquiry
— we will respond within 24 Hours
* Name
* Institution
* Products & Services of Interest
If email is not available, how else can we reach you?
How did you hear about us?